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The  study  aimed  to investigate  the  effect  of  an  early  intervention  using  human  amniotic  epithelial  cell
(hAEC)  in  a  rat  model  of  chronic  obstructive  pulmonary  disease  (COPD).  Twenty-four  speciﬁc  pathogen-
free  Wistar  rats  were  randomized  to  the control,  COPD,  and  COPD  + hAEC  groups.  COPD  was  established
by  intratracheal  LPS  injection  combined  with  smoke  fumigation  over  30  days.  On  the  ﬁrst  day  of  model
establishment  rats  in  the AEC  group  also  received  intratracheal  instillation  of  500,000  hAECs  isolated  from
the placenta  of  healthy  donors.  The  mean  linear  intercept  (MLI)  and  mean  alveolar  number  (MAN)  were
used to assess  the  degree  of  lung  emphysema.  IL-8  was  measured  using  a radioimmunoassay,  surfactant
protein  D  (SP-D)  was  measured  by ELISA,  and  matrix  metalloproteinase  (MMP)2  and  MMP8  expression
was  assessed  by PCR.  Smoke  fumigation  combined  to LPS  injection  successfully  established  a COPD  ratatrix metalloproteinase 2
atrix metalloproteinase 8
model  with signiﬁcant  emphysema  and  airway  inﬂammation,  elevated  MLI and MAN,  elevated  systemic
and lung  tissue  levels  of  IL-8 and  SP-D  (P <  0.05),  and  high  expression  of MMP2  and  MMP8.  Rats  in the
COPD  + hAEC  group  exhibited  alleviated  lung  damage,  MLI and  MAN  (P < 0.05), reduced systemic  and  lung
tissue levels  of  IL-8  and  SP-D  (P <  0.05)  and  MMP2  and  MMP8  expression  (P  < 0.05).  Early  intervention
using  hAECs  could  delay  disease  progression  in  rats  with  COPD.
© 2016  The  Authors.  Published  by Elsevier  GmbH.  This  is an  open  access  article  under  the  CC  BY. Introduction
Chronic obstructive pulmonary disease (COPD) affects 329
illion people worldwide [1]. COPD is characterized by the devel-
pment of abnormal inﬂammatory responses to the inhalation
f noxious particles, most commonly caused by long-term expo-
ure to cigarette smoke. The pathological features of COPD include
eripheral airway inﬂammation, lung parenchyma destruction, and
mphysema [2]. Smoking can induce the aggregation and activation
f alveolar macrophages and neutrophils, and trigger the release of
lastase, especially matrix metalloproteinases (MMP), leading to
mphysema and alveolar wall damage [3–5].MMPs  are mainly produced by neutrophils, alveolar
acrophages, and airway epithelial cells. MMPs  participate
n airway inﬂammation by impairing the support of airway
∗ Corresponding author at: Graduate School, Hebei Medical University, Shiji-
zhuang 050017, China.
E-mail address: czq0423rsp@126.com (Z. Chen).
ttp://dx.doi.org/10.1016/j.prp.2016.08.014
344-0338/© 2016 The Authors. Published by Elsevier GmbH. This is an open access articlicense  (http://creativecommons.org/licenses/by/4.0/).
structural tissues, and by inducing chemotaxis, migration, and
aggregation of inﬂammatory cells, as well as the release of various
inﬂammatory cytokines and growth factors [6]. The neutrophil
MMP2  and MMP8  belong to the gelatinase and collagenase sub-
groups, respectively, and can also induce the expression of IL-8,
thereby further aggravating airway inﬂammation [7,8]. IL-8 is an
important mediator of various inﬂammatory diseases, and medi-
ates inﬂammatory reactions and immune regulation by regulating
the aggregation and activation of neutrophils and T lymphocytes
during inﬂammation [9,10]. IL-8 is recognized as a key factor to
the development of COPD [9].
Studies have suggested that human amniotic epithelial cells
(hAECs) can alleviate inﬂammation and play a role in the repair of
lung injury by regulating the function of macrophages and reducing
the aggregation of inﬂammatory cells [11–15]. The objective of this
study was  to investigate the effects of an early intervention using
hAEC in a rat model of COPD. We  established a rat model of COPD
by LPS injection combined with cigarette smoke fumigation. Dur-
ing model establishment, rats in the COPD + hAEC group received
intratracheal hAECs instillation. Results showed that hAECs infu-
le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ion inhibited local and systemic inﬂammatory reactions that were
xacerbated by COPD, thereby delaying the progress of COPD.
. Materials and methods
.1. Experimental animals
Twenty-four speciﬁc pathogen-free Wistar rats (male, weigh-
ng 240–260 g) were purchased from the Laboratory Animal Center
f Hebei Medical University (production license number: SCXK
Hebei) 2008-1-003). All experiments were carried out in compli-
nce with the NIH Guide for the Care and Use of Laboratory Animals
NIH Publication No. 85-23, revised 1996).
.2. Animal grouping and treatment
Supplementary Fig. S1 in the online version at DOI: 10.1016/j.
rp.2016.08.014 presents the study design. After a week of adap-
ive feeding (standard rat chow and free access to water), the
4 rats were randomized to three groups (n = 8/group): control,
OPD, and COPD + hAEC groups. COPD was established in the
OPD and COPD + hAEC groups by cigarette fumigation combined
o lipopolysaccharides (LPS) injection. The hAEC intervention was
dministered to the COPD + hAEC group.
.3. COPD model
Cigarette fumigation combined to LPS injection was performed
s previously described [16]. On days 1 and 14 of model establish-
ent, rats in the model group were administered 200 L of 1 g/L LPS
Sigma L2880; 10 mg,  USA) by tracheal injection, while the control
ats were injected with 200 L saline.
On days 2–13 d and 15–30 d of model establishment, the 24
ats were placed in a fumigating chamber (constructed by our
aboratory). For each fumigating session, rats were exposed to
he smoke of 15 cigarettes (Shijiazhuang cigarette factory, Shiji-
zhuang, China) for 20 min, twice daily, at an interval of 4 h. The
umigating chamber had three ﬂoors and rats were placed in the
pper two ﬂoors. Ventilation openings were made at the top and
ottom of the chamber, and the smoke-guiding tube directly con-
ucted the smoke into the upper ﬂoors through the sidewalls of the
hamber. The volume of the chamber was 160 L, and each cigarette
roduced approximately 500 mL  of smoke, equivalent to a smoke
oncentration of approximately 5% for each fumigation. The control
roup was not given fumigation.
.4. Preparation of human amniotic epithelial cells
hAECs were prepared as previously described [11,17]. Fresh
uman placenta was sampled from healthy women at term preg-
ancy (serum was  tested to exclude any disease), and the amniotic
embrane was mechanically separated and washed with PBS con-
aining 50 g/ml of gentamicin, 1.25 g/ml of amphotericin B,
00 g/ml of streptomycin, and 100 U/ml of penicillin (PBSA/GASP).
he placenta was then cut into pieces of 2 × 2 mm and submerged
n 0.02% EDTA-containing 0.05% trypsin (Sigma, St Louis, MO,  USA)
t 37 ◦C for 10 min. The digestion products were centrifuged for
0 min  at 37 ◦C at 200 rpm. Single-cell suspension was  obtained
fter ﬁltering the product through a 250-mesh stainless steel sieve,
nd digestion was terminated by addition of medium containing
0% FBS. The cell suspension was then ﬁltered through a 300-mesh
tainless steel sieve, and the ﬁltrate was centrifuged at 1500 rpm
or 10 min. The supernatant was discarded and the cells were
e-suspended. The suspension was then centrifuged at 800 rpm for
 min  and the supernatant was discarded, leaving hAECs at the bot-
om of the tube. Under light microscopy, the shape epithelial cells Practice 212 (2016) 1027–1033
were oval and triangular; nuclei were obvious and the cytoplasm
was homogeneous. The mouse anti-human cytokeratin 19 (CK19)
immunohistochemistry kit (Maixin Biotech company) was  used for
immunohistochemistry. The epithelial cells were positive for this
marker. After enzyme digestion, trypan blue staining was used for
determining the proportion of living cells.
Cell counting using trypan blue staining showed that >90% of the
cells were alive. hAECs were placed in the cell culture dishes at a
density of 1 × 109 cells/L and incubated at 37 ◦C in a 5% CO2 incu-
bator. Cells were prepared for CK19 immunohistochemistry after
the ﬁrst passage. Cell growth was  observed daily. Within 24 h after
primary culture inoculation, adherent cell growth could be seen.
After 72 h, cells showed rapid growth. Cells proliferated rapidly
after each passage, and cell conﬂuence reached >90%. Cells grew in
the cobblestone-like shape, and were tightly packed. Cells were like
ﬂat irregular polygons, with clear outline, and abundant cytoplasm.
A single cell was  round or oval.
2.5. Flow cytometry
2.6. Intratracheal instillation of hAECs
On the ﬁrst day of model establishment, rats in the COPD + hAECs
group were anesthetized after LPS injection with 10% pentobarbital
sodium (45 mg/kg, Sunshine Biotechnology Ltd., Shanghai, China)
and given an intratracheal instillation of hAECs at a volume of
0.2 mL  (containing 500,000 hAECs), as previously described [11,12].
2.7. Histological analysis
After model establishment (day 31), eight rats from each group
were randomly selected and 5 mL  of blood was sampled from their
femoral artery. The right lower lung lobe was sampled and ﬁxed
in 10% formalin (Shanghai chemical Reagent Company, Shang-
hai, China) for 24 h. H&E staining and Masson’s trichrome staining
were performed using standard procedures. Pulmonary tissue mor-
phology was observed under a DP73 digital microscope (Olympus,
Tokyo, Japan) after parafﬁn embedding, sectioning, and H&E stain-
ing. The mean linear intercept (MLI) and mean alveolar number
(MAN) were determined to assess the degree of lung emphysema.
H&E-stained slides were photographed using a digital microscope,
and the number of linings (NS) and the total alveolar count (Na)
were measured to calculate the area of the image (S). The MLI
and MAN  was calculated according to the formula MLI = L/NS and
MAN = Na/S. For each indicator, the average value calculated from
eight randomly selected ﬁelds was used for statistical analysis.
Masson-trichrome staining was  used for the assessment of col-
lagen deposition using an AxioVision 3.1 image analysis system
(Carl Zeiss GmbH, Oberkochen, Germany). Four to eight specimens
of right lobe stained with Masson trichrome were selected. Digi-
tal images were taken at ×440 magniﬁcation. The area of collagen
deposition (AC) and the perimeter of basement membrane of bron-
chioles (Pbm) beneath the basement membrane at 20 m depth
were measured as previously described [18]. Results are expressed
as the area of collagen deposition (AC) per the perimeter of base-
ment membrane of bronchioles (WAc/Pbm m2/m). At least 10
bronchioles were counted on each slide.
2.8. Lung function
Lung function was  assessed after measuring the weight gain of
the rats, as previously described [19]. The rats were anesthetized by
an intraperitoneal injection of 10% chloral hydrate (3 mL/kg). The
rats were ﬁxed on the operating table. The trachea was  exposed
and opened between the 2nd and 3rd cartilage rings, and rapidly
intubated. After synchronization with the ventilator, lung function
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as examined with a ML-V1-type pulmonary function analyzer
or small laboratory animals and measurement software package
Beijing Yue Hongda LLC, Beijing, China). Resistance index (RI),
orced expiratory volume (FEV), and forced vital capacity (FVC)
ere determined by the machine.
.9. Determination of serum and tissue IL-8 content
Frozen serum samples (1 mL)  and frozen lung tissue samples
50–100 mg)  were used for IL-8 detection. The IL-8 levels of the
erum and tissue homogenate (with 1 mL  of cold PBS) were deter-
ined by radioimmunoassay (Purevalley Biotech, Beijing, China)
ccording to the manufacturer’s instructions using a FJ-2021 
ounter (Xian Nuclear Instrument Factory, Xian, China).
.10. Bronchoalveolar lavage ﬂuid
After completion of the lung function test, the animals were
nesthetized with urethane (2 g/kg, i.p.). Bronchoalveolar lavage
uids (BALF) were obtained using a tracheal tube. The lungs were
ashed thrice with 0.5 mL  of sterilized normal saline containing
% bovine serum albumin (BSA) and 5000 IU/l heparin. BALF was
iluted with 1.5 mL  of Hank’s balanced salt solution (HBSS) contain-
ng 2% fetal calf serum. The samples were centrifuged at 500g at 4 ◦C
or 10 min. The pellets were resuspended with HBSS. The samples
ere stained with the Wright-Giemsa staining and 200 cells were
lassiﬁed under light microscopy. The results were expressed as the
umbers of cells of each type of cell population in one liter of BALF,
s previously described [20].
.11. Serum and tissue SP-D content
The surfactant protein D (SP-D) levels of the serum and tis-
ue samples were measured by ELISA (Westang Ltd. Co., Shanghai,
hina), according to the manufacturers’ instructions.
.12. MMP2  and MMP8  expression in lung tissue
The levels of MMP2 and MMP8  expression in lung tissue were
ssessed by PCR using the primers listed in Table 1, a PE9600 PCR
hermocycler, and total RNA extraction kit, DNase, cDNA synthesis
it, PCR reaction system, agarose, and Spain DNA Marker (Takara
io, Otsu, Japan).
Standard gel zymography was used to measure levels of MMP-
 and MMP-8. The proteins were extracted from lung tissue and
otal protein concentrations were determined with the BCA assay
Pierce Chemical, Dallas, TX, USA). Thirty micrograms of total pro-
ein were loaded and separated by a 10% Tris-glycine gel with 0.1%
elatin as substrate, washed with renaturing buffer (Invitrogen Inc.,
arlsbad, CA, USA) for 90 min  and further incubated with devel-
ping buffer (Invitrogen Inc., Carlsbad, CA, USA) at 37 ◦C for 24 h.
inally, the gels were stained with 0.5% Coomassie blue R-250 for
 h and then destained appropriately. MMP-2 and MMP-8 human
tandards (same molecular weight as the rat proteins) were loaded
n each gel to identify the bands and to standardize the measure-
ents among gels. Band intensities of total MMP-8 and MMP-2
including pro- and cleaved forms) were quantiﬁed using standard
el densitometry techniques.
.13. Total MMP  activity assay
The total activity of MMPs  was determined using a GenMed
MP  Fluorimetric Assay Kit (GenMed Scientiﬁcs Inc., Shanghai,
hina), according to the manufacturer’s instructions. Brieﬂy, the
roteins were extracted from lung tissue and total protein con-
entrations were determined with the BCA assay (Pierce Chemical, Practice 212 (2016) 1027–1033 1029
Dallas, TX, USA). Protein samples (50 L) were added to a reac-
tion mixture containing the MMP  ﬂuorescence resonance energy
transfer peptide substrate, Mca-PLGL-Dap-(Dnp)-AR-OH [21]. After
40 min  of incubation at 37 ◦C, the ﬂuorescence intensity was  mea-
sured at 330 nm/400 nm (excitation/emission) with a ﬂuorescence
microplate reader, using 7-methoxycourmarin (MCA) as the stan-
dard. One unit of MMP  activity was  deﬁned as the amount of
enzyme hydrolyzing 1 nmol of peptide substrate per min  at 37 ◦C
at pH 7.5.
2.14. Statistical analysis
Statistical analysis was  performed using SPSS 13.0 software.
Data normality was tested by the Kolmogorov-Smirnov test,
and homogeneity of variance was tested using one-way ANOVA.
Measurement data with normal distribution were presented as
mean ± standard deviation, and measurement data without normal
distribution were presented as medians and interquartile ranges.
Indicators with normal distribution and homogeneity of variance
were analyzed with one-way ANOVA modeled for a completely
randomized design with the SNK-q post hoc test. Indicators with-
out homogeneity of variance were analyzed by the nonparametric
Kruskal-Wallis H test for independent samples, and inter-group
comparisons were made by the Mann-Whitney U test. Statistical
signiﬁcance was deﬁned at P < 0.05.
3. Results
3.1. Establishment of a rat model of COPD and hAEC intervention
One month after establishment of the model, the weight of COPD
rats was  lower than that of the control rats (P < 0.05), while the
weight of the COPD + hAEC rats was higher than that of the COPD
rats (Table 2).
Rats in the COPD + hAEC group received intra-tracheal instilla-
tion of 500,000 hAECs on the ﬁrst day of COPD model establishment,
after injection of LPS, as previously described [11,12,22]. Rats that
received early intervention exhibited an intermediate status with
slight coughing and irritability, but had no sputum or wheezing.
3.2. Lung function
Lung function tests showed that the model group had a higher
RI than controls (P < 0.05) and lower FEV0.3 and FEV0.3/FVC (both
P < 0.05). The COPD + hAEC group showed lung functions that were
intermediary to the control and model groups, but nevertheless
signiﬁcantly lower than in the model group (P < 0.05) (Table 2).
3.3. Pulmonary histopathology
The lungs of the control rats showed no signiﬁcant inﬂamma-
tory cell inﬁltration and no thickening of the bronchial mucosa, but
a neat arrangement of bronchial epithelial cilia with no loss, thin-
ning, or rupturing of the alveolar walls, and no bullous formation
(Fig. 1). In contrast, the lungs of COPD rats exhibited chronic inﬂam-
matory cell inﬁltration (mainly macrophages, lymphocytes, and
monocytes), bronchial mucosal thickening, cilia loss, mucous plug
formation, and chronic inﬂammatory cell inﬁltration at airway,
alveolar wall rapture, and bullous formation, as well as thickening
of the vessel walls. The COPD model rats exhibited centrilobular
emphysema (Fig. 1A). Rats that received hAEC intervention also
exhibited the pathological changes observed in COPD rats, but the
level of inﬂammatory cell inﬁltration was  lower, and tissue damage
caused by lobular emphysema was  alleviated (Fig. 1B).
The MLI  of COPD rats (13.3 ± 1.6 × 10−5/m) was  signiﬁcantly
higher than in control rats (8.3 ± 0.6 × 10−5/m), while MAN of COPD
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Table 1
PCR primers.
Gene Primers Product (base pairs) Annealing temperature (◦SC)
MMP2  F 5′-ACGATGATGACCGGAAGTGG-3′
R 5′-GTGCTGGCAGAATAGACCCA-3′
505 53
MMP8  F 5′-TCCAGGTTACCCCACTAGCA-3′
R 5′-TGCAACTCTAGTGACTCTGCG-3′
151 52
GAPDH F 5′-GCAACTCCCATTCTTCCACC-3′
R 5′-TGGTATTCGAGAGAAGGGAGGG-3′
322 54
Table 2
Comparison of weight and lung function tests in the three groups.
Weight RI (cmH2O ml−1 s−1) FEV0.3 (mL) FEV0.3/FVC (%)
Control 366.4 ± 14.2 0.3 ± 0.1 5.0 ± 0.4 94.1 ± 3.3
COPD  301.8 ± 16.0* 0.7 ± 0.1* 3.8 ± 0.3* 63.8 ± 5.0*
COPD + hAEC 346.9 ± 10.7*,** 0.5 ± 0.1*,** 4.5 ± 0.4*, ** 79.9 ± 4.6*, **
n = 8/group.
RI: resistance index; FEV: forced expiratory volume; FVC: forced vital capacity.
* P < 0.05 vs. the control group.
** P < 0.05 vs. the COPD group.
Fig. 1. Pulmonary histopathology. (A) H&E staining of lung tissues of rats in the control, COPD, and COPD + hAEC groups (×200). (B) H&E staining of lung tissues showing
inﬂammatory cell inﬁltration. (C) Masson staining of lung tissues of rats in the control, COPD, and COPD + hAEC groups. Bar = 500 m.
Table 3
Histological characteristics of the three groups.
Group MLI  (×10−5m)  MAN  (×107/m2)
Control 8.3 ± 0.6 11.4 ± 2.3
COPD 13.3 ± 1.6* 5.0 ± 0.9*
COPD + hAEC 11.2 ± 0.8*,** 6.8 ± 1.2*, **
n = 8/group.
MLI: mean linear intercept; MAN: mean alveoli number.
* P < 0.05 vs. the control group.
** P < 0.05 vs. the COPD group.
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Table  4
Effect of hAECs on collagen deposition in lungs.
Collagen deposition (WAc/Pbm, m2/m)
Control 2.6 ± 0.6
COPD 6.9 ± 0.9*
COPD + hAEC 4.6 ± 0.8*,**
n = 8/group.
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Table 6
IL-8 and pulmonary SP-D levels among groups.
Group IL-8 (ng/ml) SP-D (ng/ml)
Serum Control 0.24 ± 0.09 28.44 ± 4.26
COPD 0.47 ± 0.10* 55.99 ± 7.81*
COPD + hAEC 0.32 ± 0.10**,# 37.62 ± 6.55*,#
Tissue Control 0.24 ± 0.04 37.63 ± 7.70
COPD 0.40 ± 0.37* 68.23 ± 6.55*
COPD + hAEC 0.24 ± 0.02*,** 44.13 ± 10.29*, #
n = 8/group.
SP-D: surfactant protein D.
* P < 0.05 vs. the control group.
** P > 0.05 vs. the control group.
# P < 0.05 vs. the COPD group.
Table 7
Comparison of MMP8  and MMP2  activity among groups.
MMP2  (U/mg of protein) MMP8  (U/mg  of protein)
Control 3.00 ± 0.62 0.42 ± 0.04
COPD 4.86 ± 0.36* 0.60 ± 0.05*
COPD + hAEC 3.990.50*, ** 0.53 ± 0.03*, **
Increased serum levels of SP-D indicate damage of pulmonary
T
W
n* P < 0.05 vs. the control group.
** P < 0.05 vs. the COPD group.
ats (5.0 ± 0.8 × 107/m2) was signiﬁcantly lower than in control
ats (11.4 ± 2.3 × 107/m2). Both indexes were signiﬁcantly better
n COPD + hAEC rats (11.2 ± 0.8 × 10−5/m and 6.8 ± 1.2 × 107/m2)
P < 0.05) (Table 3).
The COPD group showed more collagen deposition than the con-
rol group (P < 0.05). The COPD + hAEC group showed an amount of
ollagen deposition intermediary between the control and COPD
roups, but lower than that of the COPD group (P < 0.05) (Fig. 1C
nd Table 4).
.4. Lung inﬂammation
The white blood cell counts and neutrophils proportions in
ALF of the COPD group were higher than that of the control and
OPD + hAECs groups, while macrophage and lymphocyte propor-
ions in the BALF of the COPD group were lower than that of the
ontrol and COPD + hAECs groups (Table 5).
.5. Pulmonary and systemic IL-8 and SP-D levels
The serum and tissue levels of IL-8 in COPD rats
0.47 ± 0.10 ng/ml and 0.40 ± 0.37 ng/ml) was signiﬁcantly higher
han that of control rats (0.24 ± 0.09 ng/ml and 0.24 ± 0.04 ng/ml)
P < 0.05), but both measurements were signiﬁcantly improved
y hAEC intervention (0.32 ± 0.10 ng/ml and 0.24 ± 0.02 ng/ml)
P < 0.05), reducing the levels of IL-8 in the serum and tissue to the
aseline levels observed in control animals (P > 0.05) (Table 6).
The serum and tissue levels of SP-D in COPD rats
55.99 ± 7.81 ng/ml and 37.63 ± 7.70 ng/ml) was signiﬁ-
antly higher than in control rats (28.44 ± 4.26 ng/ml and
8.23 ± 6.55 ng/ml) (P < 0.05), but both measurements were
igniﬁcantly improved by hAEC intervention (37.62 ± 6.55 ng/ml
nd 44.13 ± 10.29 ng/ml) (P < 0.05), reducing the levels of SP-D in
he serum and tissue to the baseline levels observed in control
nimals (P > 0.05) (Table 6).
.6. Pulmonary and systemic MMP2  and MMP8  expression
RT-PCR was performed to detect MMP2  and MMP8  mRNA
xpression in lung tissues of rats. MMP2  and MMP8  expression was
igniﬁcantly higher in COPD rats compared with controls, but sig-
iﬁcantly decreased in COPD + hAECs rats compared with COPD rats
Fig. 2).
able 5
hite blood cell count and classiﬁcation in BALF.
WBC  (×105cells/ml) Neutrophils
Control 4.0 ± 0.8 2.3 ± 1.0 
COPD 9.8 ± 1.1* 24.5 ± 6.1* 
COPD + hAEC 6.2 ± 1.0*,** 6.1 ± 2.7*, **
 = 8/group.
* P < 0.05 vs. the control group.
** P < 0.05 vs. the COPD group.n = 8/group.
* P < 0.05 vs. the control group.
** P < 0.05 vs. the COPD group.
3.7. MMP2 AND MMP8 activity
MMP2  and MMP8  activity was higher in the COPD group com-
pared with the control group (P < 0.05), while the COPD + hAEC
group showed MMP2  and MMP8  activity that was intermediary
to that of the control and COPD groups, but lower than that of the
COPD group) P < 0.05) (Table 7).
4. Discussion
hAECs have been reported to regulate inﬂammatory reactions
and mediate lung injury repair [11–15]. This study aimed to inves-
tigate the effects of hAEC early intervention in a rat model of COPD.
We established a rat model of COPD by LPS injection combined
with smoke fumigation. During model establishment, rats in the
AEC group received intratracheal hAEC instillation.
Smoke fumigation combined to LPS injection was used success-
fully to establish a rat model of COPD with signiﬁcant emphysema
and airway inﬂammation, elevated MLI  and MAN, and elevated sys-
temic and lung tissue levels of IL-8. IL-8 is recognized as a key factor
of the development of COPD [9]. COPD model animals also exhib-
ited elevated SP-D levels, and enhanced expression of MMP2  and
8. Previous reports have highlighted the elevation of serum and
bronchoalveolar lavage SP-D levels in patients with COPD, and that
SP-D levels were positively associated with patients’ history and
amount of cigarette smoking [3–5]. MMPs  have been implicated in
the induction of emphysema and alveolar wall damage [3–5].tissues and decline of lung function, while decreased SP-D in the
serum and increased SP-D in bronchoalveolar lavage ﬂuid indi-
cate alleviation of COPD, which is of great signiﬁcance for disease
 (%) Macrophages (%) Lymphocytes (%)
87.2 ± 5.7 10.2 ± 3.2
69.1 ± 7.6* 6.4 ± 2.3*
79.7 ± 6.7*,** 14.2 ± 4.3*, **
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[Fig. 2. MMP2  and MMP8  expression in lung tissues. A, mRNA expression
onitoring and prognosis [23]. SP-D could be an indicator for
nﬂammation monitoring and prognosis during COPD and its treat-
ents.
Developing a drug or biological agent that could reduce inﬂam-
ation should help delaying the progress of COPD. In the present
tudy, hAEC infusion inhibited local and systemic inﬂammatory
eactions that were exacerbated by COPD, thereby delaying the
rogress of COPD. Rats in the COPD + hAEC group exhibited allevi-
ted lung damage, MLI  and MAN, reduced systemic and lung tissue
evels of IL-8 and SP-D, and MMP2  and MMP8  expression. These
ndexes not only indicate that hAEC infusion effectively reduced
nﬂammation, but that this process could be measured in the cir-
ulating blood, allowing the therapeutic intervention to be easily
onitored.
The human amnion is the tissue located at the innermost layer of
he human placenta, and as is widely available and easily collected.
AECs may  retain some or even full multi-differentiation poten-
ial, exhibiting a higher degree of stem-ability, and high similarity
o embryonic stem cells [7]. Due to their anti-inﬂammatory and
egenerative features, hAECs may  represent a promising cellular
reatment for COPD, and these therapies should be further investi-
ated in a wider range of animal models of inﬂammatory diseases
24].P2; B, mRNA expression of MMP8. *P < 0.05 compared with Con group.
Of course, the present study is not without limitations. All mod-
els of chronic lung injury have their strengths and limitations [25].
In addition, it has to be highlighted that the present study used
hAECs as prevention and not as treatent of COPD, as previously
suggested [26]. Finally, the effects of hAECs on rate without CPOD
were not investigated. Additional studies are necessary to examine
the effects of hAECs on chronic inﬂammatory lung diseases.
In this study, hAECs instillation was  conducted during the ﬁrst
stage of COPD model establishment. This reduced the damage to
MLI, decreased serum and tissue IL-8 and SP-D levels, improved
alveolar surface area, and prevented bullae formationDelayed
COPD progression after early intervention might be attributed to
the anti-inﬂammatory role of hAECs. However, whether this result
could be achieved with intraperitoneal injection or intravenous
injection, and whether this is associated with the regenerative
capability of hAECs requires further investigation.
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